Brandon Driscoll, MASc

Brandon is involved many facets of QIPCM and focusses mainly on helping investigators link their multi-center clinical trial imaging needs with QIPCM’s available services and resources. Brandon has led the development of the QIPCM Dosimetry program utilized for the OZM-067 NET-PRRT trial and adapted for use for standard of care Lutathera imaging at the Princess Margaret Cancer Centre. He is also the primary contact at QIPCM for multi-center scanner QA and validation for functional imaging including PET-CT/MR and DCE-CT.

Brandon obtained his Bachelor’s degree (B.A.Sc.) in Chemical Engineering with Software Option from the University of Waterloo in 2004. Throughout his co-op work terms Brandon gained experience in many facets of engineering from petro-chemicals and the automotive industry to computer programming. He went on to complete a Masters of Biomedical Engineering (M.A.Sc.) from the Institute of Biomaterials & Biomedical Engineering at the University of Toronto. His thesis focused on the development of an inhibitory peptide for the TGF-beta signal pathway in hematopoietic stem cells.